Alkem Laboratories has nearly doubled its planned investment for a greenfield pharmaceutical manufacturing facility in Ujjain, Madhya Pradesh, raising the outlay from ₹533 crore to ₹1,036 crore. The board approved the increase on April 2, 2026. The facility will produce tablets, capsules, and injectables to meet rising domestic and international demand.
Glimpse:
The project is being developed on approximately 30 acres of land allotted in the Vikram Udyogpuri area near the Delhi, Mumbai Industrial Corridor (DMIC). The enhanced investment will be deployed in phases to expand production capacity and capabilities. The unit is expected to boost operational efficiency through better logistics and contribute to regional economic development by generating employment opportunities.
Alkem Laboratories Limited has significantly scaled up its capital expenditure plans for a new manufacturing unit in Ujjain, Madhya Pradesh. The company’s board of directors approved an increase in investment from ₹533 crore to ₹1,036 crore on April 2, 2026, nearly doubling the original outlay. This revised amount will be utilised in a phased manner to set up a modern greenfield formulations facility.
The upcoming plant will focus on producing a wide range of pharmaceutical products, including tablets, capsules, and injectables. It is strategically located on about 30 acres in the Vikram Udyogpuri industrial area, offering strong logistical advantages due to its proximity to the Delhi,Mumbai Industrial Corridor (DMIC). This positioning is expected to improve supply chain efficiency for both raw material procurement and finished goods distribution to domestic and global markets.
The enhanced investment reflects Alkem’s long term strategy to strengthen its manufacturing footprint in India amid growing demand for quality pharmaceutical products. Once operational, the facility is anticipated to create new employment opportunities and support industrial growth in the region.
The development was disclosed to stock exchanges in compliance with SEBI listing obligations. This move comes alongside Alkem’s ongoing efforts to expand its presence in both generic formulations and specialty segments.
“The Board of Directors has approved an increase in the total investment from up to ₹533 crore to up to ₹1,036 crore, to be made in a phased manner for setting up of the manufacturing facility in Ujjain.”
By
HB Team
